Covered recipient · General Payments record
RONALD F TUTRONE
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,792.15
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,680.36 | 57 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $111.79 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sumitomo Pharma America, Inc. | $418.08 | 14 |
| Dendreon Pharmaceuticals LLC | $365.69 | 9 |
| PROGENICS PHARMACEUTICALS, INC. | $285.64 | 5 |
| ACCORD HEALTHCARE, INC. | $141.40 | 4 |
| Janssen Biotech, Inc. | $129.51 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $116.75 | 5 |
| Ferring Pharmaceuticals Inc. | $100.34 | 5 |
| PFIZER INC. | $76.93 | 6 |
| Endo USA, Inc. | $53.13 | 3 |
| Novo Nordisk Inc | $45.50 | 2 |
| E.R. Squibb & Sons, L.L.C. | $33.30 | 1 |
| Blue Earth Diagnostics Limited | $25.88 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD F TUTRONE
NPI 1265495204 · CMS profile ID 284752
Allopathic & Osteopathic Physicians / Urology
BALTIMORE, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- RONALD F TUTRONE, NPI 1265495204, CMS profile ID 284752, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265495204?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $1,792.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | $20.64 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137515952 | CMS |
| Janssen Biotech, Inc. | $72.01 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078710040 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.97 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086192492 | CMS |
| Dendreon Pharmaceuticals LLC | $10.63 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149325200 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $113.19 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128515033 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $19.55 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128513663 | CMS |
| PFIZER INC. | $13.09 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131107183 | CMS |
| Dendreon Pharmaceuticals LLC | $16.09 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149325198 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $54,891.99 | 11 |
| PY2025 | Principal investigator | $4,225,291.52 | 215 |
| PY2024 | Recipient | $7,737.86 | 5 |
| PY2024 | Principal investigator | $2,849,872.01 | 168 |
| PY2023 | Recipient | $19,163.31 | 19 |
| PY2023 | Principal investigator | $2,270,234.16 | 206 |
| PY2022 | Recipient | $1,316.00 | 1 |
| PY2022 | Principal investigator | $2,576,328.25 | 318 |
| PY2021 | Principal investigator | $1,359,876.91 | 251 |
| PY2020 | Principal investigator | $2,848,670.78 | 347 |
| PY2019 | Principal investigator | $1,914,676.85 | 329 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
226 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $21,041.48 | 12/31/2025 | Non-covered Recipient Entity Chesapeake Urology | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930651 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 12/28/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,502.00 | 12/26/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382959 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 12/24/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739410 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 12/24/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 12/12/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227868 |
| Principal investigator 1 | MEDIVATION LLC. | $1,063.95 | 12/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720299 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 12/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740387 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 12/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740457 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $8,450.00 | 12/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $304.00 | 12/01/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,670.00 | 12/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382732 |
| Principal investigator 1 | AstraZeneca UK Limited | $26,800.00 | 11/14/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES, PA | a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate | No dispute reported | 06/30/2026 | 1185555549 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 11/10/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727839 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 11/08/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727471 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $5,000.00 | 11/06/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892574 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $46,947.46 | 11/06/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Pa | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235998168 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 11/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739648 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 11/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740040 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 11/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,670.00 | 11/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382838 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,748.00 | 10/30/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225408916 |
| Principal investigator 1 | Celgene Corporation | $36,000.00 | 10/23/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Pa | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1222305286 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 10/20/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726700 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 10/19/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727473 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,004.00 | 10/06/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382790 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 10/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739945 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 10/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740601 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 10/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740639 |
| Principal investigator 1 | PFIZER INC. | $123,221.03 | 09/30/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727461 |
| Principal investigator 1 | PFIZER INC. | $123,221.03 | 09/29/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,271.00 | 09/26/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382884 |
| Recipient | PFIZER INC. | $940.00 | 09/25/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $235.20 | 09/22/2025 | Non-covered Recipient Entity Chesapeake Uro | A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175230695 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.64 | 09/19/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382822 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/10/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727547 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/09/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727941 |
| Principal investigator 1 | Janssen Research & Development, LLC | $954.00 | 09/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382893 |
| Principal investigator 1 | Janssen Research & Development, LLC | $304.00 | 09/05/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227533 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 09/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742725 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 09/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755764 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 09/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756498 |
| Recipient | PFIZER INC. | $3,200.00 | 08/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726598 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/21/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725582 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/20/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726698 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 08/11/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727765 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 08/10/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727939 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 08/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892356 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $23,000.00 | 08/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892359 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,450.00 | 08/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892362 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,500.00 | 08/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892366 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 08/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 08/01/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 08/01/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227773 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 08/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743321 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 08/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755560 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,248.50 | 08/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641791 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,124.25 | 08/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641841 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,250.00 | 07/28/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies | No dispute reported | 06/30/2026 | 1225413026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,004.00 | 07/28/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382814 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 07/22/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727763 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 07/21/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724720 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $436.00 | 07/18/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402261 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/14/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726848 |
| Recipient | PFIZER INC. | $330.00 | 07/11/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228722498 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/11/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727937 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 07/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640242 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 07/04/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227781 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $19,613.00 | 07/03/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402263 |
| Principal investigator 1 | PFIZER INC. | $77,013.15 | 07/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727915 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 07/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743551 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 07/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756186 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 07/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756795 |
| Principal investigator 1 | PFIZER INC. | $77,013.15 | 07/01/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725584 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $22,001.50 | 06/30/2025 | Non-covered Recipient Entity ADVANCED UROLOGY PLLC | ProvONE | No dispute reported | 06/30/2026 | 1247892257 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $125.00 | 06/30/2025 | Non-covered Recipient Entity ADVANCED UROLOGY PLLC | ProvONE | No dispute reported | 06/30/2026 | 1247892263 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/23/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753578 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/21/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753583 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/21/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.64 | 06/16/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,271.00 | 06/13/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $823.20 | 06/12/2025 | Non-covered Recipient Entity Chesapeake Uro | A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175230589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,004.00 | 06/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382967 |
| Recipient | Dendreon Pharmaceuticals LLC | $19,000.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891677 |
| Recipient | Dendreon Pharmaceuticals LLC | $6,500.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891680 |
| Recipient | Dendreon Pharmaceuticals LLC | $211.99 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891684 |
| Recipient | Dendreon Pharmaceuticals LLC | $16,000.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891689 |
| Recipient | Dendreon Pharmaceuticals LLC | $6,500.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891692 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $16,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247891953 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $13,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247891957 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $19,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892192 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $13,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892197 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $211.99 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892201 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $21,102.00 | 06/02/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402265 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752636 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/01/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751647 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/01/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755161 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 05/27/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752040 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,862.90 | 05/26/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES, LLC | A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1190303317 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,670.00 | 05/23/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382931 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719709 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720529 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724354 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724460 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778498 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789881 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789886 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789963 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790076 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790279 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790506 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790607 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791013 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791149 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791158 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791663 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792025 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792171 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792289 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792529 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792688 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792753 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792900 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792956 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792960 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793163 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793228 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793445 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793571 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793653 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793984 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228794035 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 05/22/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228794039 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 05/22/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753883 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 05/22/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754886 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228723218 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $60.00 | 05/07/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634223 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 05/05/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753179 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 05/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753507 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 05/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754533 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 04/30/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227849 |
| Recipient | PFIZER INC. | $940.00 | 04/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,670.00 | 04/21/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382996 |
| Principal investigator 1 | PFIZER INC. | $123,216.32 | 04/14/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753758 |
| Principal investigator 1 | PFIZER INC. | $123,216.32 | 04/12/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751744 |
| Principal investigator 1 | PFIZER INC. | $123,221.04 | 04/12/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755126 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 04/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632679 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,281.00 | 04/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632693 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,427.00 | 04/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632720 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/03/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753880 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,882.00 | 04/02/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402429 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753502 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756239 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228779260 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228781318 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789905 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790136 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792907 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 04/01/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793323 |
| Principal investigator 1 | Janssen Research & Development, LLC | $954.00 | 03/31/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382975 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $436.00 | 03/28/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402431 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/14/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753754 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 03/13/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227739 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/13/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752036 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/13/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228757683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 03/07/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382915 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 03/04/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752953 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720465 |
| Principal investigator 1 | MEDIVATION LLC. | $1,063.95 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720629 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722512 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724034 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774310 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774445 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774612 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774649 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774871 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775037 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775096 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775454 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775611 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776042 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776407 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776482 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777466 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777746 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777800 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778059 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228784621 |
| Principal investigator 1 | MEDIVATION LLC. | $484.62 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228784653 |
| Principal investigator 1 | MEDIVATION LLC. | $227.55 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785749 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 03/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786098 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 03/03/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753174 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 03/03/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755209 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $536.00 | 02/25/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225404580 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,624.00 | 02/18/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402425 |
| Principal investigator 1 | Eli Lilly and Company | $5,410.00 | 02/18/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY | CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1187878087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.64 | 02/14/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,236.00 | 02/10/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175382777 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $15,855.00 | 02/07/2025 | Non-covered Recipient Entity Chesapeake Urology Associates, Llc D/b/a Chesapeake Urology Research | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402427 |
| Principal investigator 1 | Eli Lilly and Company | $24,885.87 | 02/06/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | No dispute reported | 06/30/2026 | 1187878839 |
| Principal investigator 1 | Janssen Research & Development, LLC | $954.00 | 02/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175382739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $681.00 | 02/03/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | Protocol 212082PCR2005 ?A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease | No dispute reported | 06/30/2026 | 1175382784 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 02/03/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753886 |
| Recipient | PFIZER INC. | $940.00 | 02/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770949 |
| Principal investigator 1 | PFIZER INC. | $30,804.08 | 02/01/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753750 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 02/01/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228759169 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/28/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777487 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $536.00 | 01/27/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225405238 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/23/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723982 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/22/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720321 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 01/22/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228758227 |
| Principal investigator 1 | PFIZER INC. | $77,010.20 | 01/13/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753587 |
| Principal investigator 1 | PFIZER INC. | $77,010.20 | 01/12/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751639 |
| Principal investigator 1 | PFIZER INC. | $77,013.15 | 01/12/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755130 |
| Principal investigator 1 | Janssen Research & Development, LLC | $152.00 | 01/10/2025 | Non-covered Recipient Entity Chesapeake Uro Associates, Pa | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175227842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 01/09/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | Protocol 212082PCR2005 ?A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease | No dispute reported | 06/30/2026 | 1175382831 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $926,348.65 | 01/08/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES, PA | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185555551 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/06/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751642 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775068 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777951 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778075 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778250 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778373 |
| Principal investigator 1 | MEDIVATION LLC. | $1,002.45 | 01/02/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786724 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722470 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 01/02/2025 | Non-covered Recipient Entity Chesapeake Urology Research Associates | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755106 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 2 |
| PY2024 | Value of interest | $80,182.17 | 2 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $78,612.01 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $37,950.63 | 1 |
| PY2021 | Amount invested | $0.00 | 1 |
| PY2021 | Value of interest | $35,239.87 | 1 |
| PY2020 | Amount invested | $0.00 | 1 |
| PY2020 | Value of interest | $90,358.69 | 1 |
| PY2019 | Amount invested | $0.00 | 1 |
| PY2019 | Value of interest | $39,494.35 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
7 records · PY2019–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | SN Holdings, LLC | $0.00 | $204.38 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124771713 |
| PY2024 | SN Holdings, LLC | $0.00 | $79,977.79 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124773461 |
| PY2023 | SN Holdings, LLC | $0.00 | $78,612.01 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1032887575 |
| PY2022 | SN Holdings, LLC | $0.00 | $37,950.63 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 941609541 |
| PY2021 | SN Holdings, LLC | $0.00 | $35,239.87 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 820125501 |
| PY2020 | UroGPO LLC | $0.00 | $90,358.69 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 737139319 |
| PY2019 | UroGPO LLC | $0.00 | $39,494.35 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 690774895 |